Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CDTX
stocks logo

CDTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.508
-71.93%
--
--
-1.640
-1.2%
--
--
-2.140
+29.7%
Estimates Revision
The market is revising No Change the revenue expectations for Cidara Therapeutics, Inc. (CDTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 249.06%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+26.96%
In Past 3 Month
Stock Price
Go Up
up Image
+249.06%
In Past 3 Month
Wall Street analysts forecast CDTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDTX is 209.67 USD with a low forecast of 173.00 USD and a high forecast of 221.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast CDTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDTX is 209.67 USD with a low forecast of 173.00 USD and a high forecast of 221.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
6 Hold
0 Sell
Hold
Current: 220.500
sliders
Low
173.00
Averages
209.67
High
221.50
Current: 220.500
sliders
Low
173.00
Averages
209.67
High
221.50
Guggenheim
Buy -> Neutral
downgrade
2025-11-17
Reason
Guggenheim
Price Target
2025-11-17
downgrade
Buy -> Neutral
Reason
Guggenheim downgraded Cidara Therapeutics (CDTX) to Neutral from Buy without a price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.
BofA
Tim Anderson
Buy
maintain
$98 -> $105
2025-11-17
Reason
BofA
Tim Anderson
Price Target
$98 -> $105
2025-11-17
maintain
Buy
Reason
BofA analyst Tim Anderson raised the firm's price target on Merck (MRK) to $105 from $98 and keeps a Buy rating on the shares. The Cidara (CDTX) deal is a "reasonable" one, as the company's experimental flu drug is a novel asset with a high likelihood of technical success and complementary to Merck's Infectious Disease franchise, the analyst tells investors in a research note. The firm added that Merck shares are too cheap for the growth it should be able to deliver on a near- and long-term basis.
Morgan Stanley
Maxwell Skor
Overweight -> Equal Weight
downgrade
$221.50
2025-11-16
Reason
Morgan Stanley
Maxwell Skor
Price Target
$221.50
2025-11-16
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley analyst Maxwell Skor downgraded Cidara Therapeutics (CDTX) to Equal Weight from Overweight with a $221.50 price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.
H.C. Wainwright
Sara Nik
Buy -> Neutral
downgrade
2025-11-14
Reason
H.C. Wainwright
Sara Nik
Price Target
2025-11-14
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Sara Nik downgraded Cidara Therapeutics (CDTX) to Neutral from Buy without a price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.
Needham
Buy
to
Hold
downgrade
2025-11-14
Reason
Needham
Price Target
2025-11-14
downgrade
Buy
to
Hold
Reason
Needham downgraded Cidara Therapeutics (CDTX) to Hold from Buy without a price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.
RBC Capital
Outperform -> Sector Perform
downgrade
$145
2025-11-14
Reason
RBC Capital
Price Target
$145
2025-11-14
downgrade
Outperform -> Sector Perform
Reason
RBC Capital downgraded Cidara Therapeutics (CDTX) to Sector Perform from Outperform with a price target of $221.50, up from $145, after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cidara Therapeutics Inc (CDTX.O) is -27.43, compared to its 5-year average forward P/E of -3.92. For a more detailed relative valuation and DCF analysis to assess Cidara Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.92
Current PE
-27.43
Overvalued PE
2.46
Undervalued PE
-10.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.87
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.59
Undervalued EV/EBITDA
-4.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
59.02
Current PS
0.00
Overvalued PS
268.39
Undervalued PS
-150.36
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CDTX News & Events

Events Timeline

(ET)
2025-11-24
08:01:22
Cidara Therapeutics Achieves Enrollment Goal for Phase 3 ANCHOR Trial
select
2025-11-17 (ET)
2025-11-17
11:05:10
Merck anticipates a $5 billion potential from Cidara's influenza medication, according to Reuters.
select
link
2025-11-14 (ET)
2025-11-14
12:00:03
Cidara Therapeutics Sees 105.6% Surge in Stock Price
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
00:10 AMBarron's
The Biotech Sector Is Stronger Than Investors Realize: Key Stocks to Monitor.
  • Biotech Sector Performance: The State Street SPDR S&P Biotech ETF has shown a poor performance since early 2021, indicating challenges for investors in the biotech sector.
  • Investor Sentiment: The overall trend in the biotech market suggests a significant downturn, leading to a negative outlook for potential investors.
[object Object]
Preview
9.0
11-30NASDAQ.COM
Is This Blue Chip Pharmaceutical Stock Worth Buying After Its 3.8% Surge?

  • Merck's Recent Success: Merck has achieved a significant phase 2 win with its drug sotatercept, which is now approved for treating pulmonary arterial hypertension and has the potential to expand into a rare condition with no current treatments, boosting investor confidence.

  • Strategic Acquisitions: The company is acquiring Cidara Therapeutics for $9.2 billion to gain access to CD388, a promising influenza therapy, and is also awaiting FDA approval for a new HIV treatment, further diversifying its portfolio.

  • Keytruda Developments: Merck has introduced a subcutaneous version of its blockbuster drug Keytruda, which, while not covering all original indications, helps mitigate the impact of patent expiration and supports the company's ongoing revenue.

  • Long-term Outlook: Despite challenges in its vaccine business, Merck's strong pipeline, consistent dividend growth, and strategic investments position it as a reliable blue-chip stock for long-term investors.

[object Object]
Preview
8.5
11-29PRnewswire
Gulf Island Fabrication (GIFI) to Sell to IES Holdings for $12.00 per Share, Shareholders Urged to Act
  • Shareholder Rights Investigation: Halper Sadeh LLC is investigating Gulf Island Fabrication, Inc. (NASDAQ:GIFI) regarding its sale to IES Holdings, Inc. for $12.00 per share in cash, potentially violating shareholder rights, prompting shareholders to act swiftly to protect their interests.
  • Merger Transaction Impact: This transaction will affect GIFI shareholders' equity, necessitating an understanding of the deal's details and its potential implications for future investments to make informed decisions.
  • Legal Support Offered: Halper Sadeh LLC provides free legal consultations to assist shareholders in understanding their rights and options, ensuring they receive fair compensation in the transaction.
  • Commitment to Investor Protection: The firm is dedicated to protecting investors globally, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its expertise in securities fraud cases.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cidara Therapeutics Inc (CDTX) stock price today?

The current price of CDTX is 220.5 USD — it has decreased -0.22 % in the last trading day.

arrow icon

What is Cidara Therapeutics Inc (CDTX)'s business?

Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.

arrow icon

What is the price predicton of CDTX Stock?

Wall Street analysts forecast CDTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDTX is 209.67 USD with a low forecast of 173.00 USD and a high forecast of 221.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cidara Therapeutics Inc (CDTX)'s revenue for the last quarter?

Cidara Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Cidara Therapeutics Inc (CDTX)'s earnings per share (EPS) for the last quarter?

Cidara Therapeutics Inc. EPS for the last quarter amounts to -3.10 USD, increased 26.53 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cidara Therapeutics Inc (CDTX)'s fundamentals?

The market is revising No Change the revenue expectations for Cidara Therapeutics, Inc. (CDTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 249.06%.
arrow icon

How many employees does Cidara Therapeutics Inc (CDTX). have?

Cidara Therapeutics Inc (CDTX) has 38 emplpoyees as of December 05 2025.

arrow icon

What is Cidara Therapeutics Inc (CDTX) market cap?

Today CDTX has the market capitalization of 6.93B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free